NovaBay Pharmaceuticals rebrands to Stablecoin Development Corporation and acquires approximately 2.06 billion SKY tokens (8.78% of total supply), marking a bold strategic shift from pharmaceuticals to blockchain. The move grants significant governance influence over Sky Protocol and triggers a 300% surge in SKY trading volume.
NovaBay Pharmaceuticals pivots to crypto by acquiring ~8.78% of SKY tokens (2.06B) and rebranding to Stablecoin Development Corporation. The move marks a rare pharma-to-blockchain transformation, granting significant governance power in the Sky protocol.
U.S.-listed NovaBay Pharmaceuticals rebrands to Stablecoin Development Corporation after acquiring ~2.06 billion SKY tokens (8.78% of supply) and pivoting from dermatology to blockchain governance. The move triggers a 300% volume spike and raises questions about corporate influence in DeFi protocols.
U.S.-listed pharma firm NovaBay acquired 2.06 billion SKY tokens (8.78% of supply) and rebranded to Stablecoin Development Corporation, marking a dramatic shift from pharmaceuticals to blockchain. The move sparked a 300% surge in SKY trading volume and 15% price increase.
NYSE-listed NovaBay Pharmaceuticals acquired approximately 2.06 billion SKY tokens (8.78% of supply) for over $130 million and rebranded to Stablecoin Development Corporation (SDEV), marking a bold pivot from pharma to blockchain. The move triggered a 15% SKY price surge and 300% volume spike.
NYSE-listed NovaBay Pharmaceuticals rebrands as Stablecoin Development Corporation after acquiring ~2.06 billion SKY tokens (8.78% of supply), pivoting from pharma to DeFi. The move triggered a 300% surge in SKY trading volume.
NYSE-listed NovaBay Pharmaceuticals rebranded to Stablecoin Development Corporation after acquiring ~2.06 billion SKY tokens (8.78% of supply) for over $130 million. The move triggered a 300% volume spike and 15% price surge in SKY, marking a major pharma-to-crypto transformation.
NovaBay Pharmaceuticals acquired 2.06 billion SKY tokens (8.78% of supply) and rebranded to Stablecoin Development Corporation, marking a major shift from pharma to blockchain governance.
